Skip to content
PubMed This is a summary of 39 peer-reviewed journal articles Updated
Neurology

Your First Steps with Sjögren-Larsson Syndrome

At a Glance

Sjögren-Larsson Syndrome (SLS) is a rare genetic condition characterized by a "classic triad" of symptoms: dry, scaly skin (ichthyosis), muscle stiffness (spasticity), and intellectual disability. It is caused by an ALDH3A2 gene mutation and requires coordinated care from multiple specialists.

Receiving a diagnosis of Sjögren-Larsson Syndrome (SLS) is a profound and often devastating moment. It is completely normal to feel grief, fear, and overwhelm, especially since you may have never heard the name before. It is an exceptionally rare condition, affecting approximately 0.4 per 100,000 individuals worldwide [1]. Because of its rarity, it is common for families to find that local doctors have limited experience with the syndrome [2]. This guide is designed to help you ground yourself in the facts, understand the biological journey ahead, and advocate for your child’s best possible care.

While SLS is a lifelong genetic condition without a cure, it is important to know that many symptoms are manageable [3]. Modern medicine offers treatments to improve skin comfort, enhance mobility, and support developmental progress [4][5]. Connecting with rare disease advocacy groups and other families who understand this unique journey can help remind you that you are not alone.

Understanding the “Classic Triad”

SLS is typically identified by three core features, often referred to as the “classic triad”:

  1. Congenital Ichthyosis: This is dry, thickened, and scaly skin that is usually present from birth [2][6].
  2. Spasticity: This refers to stiff or tight muscles, which may affect the legs (spastic diplegia) or all four limbs (spastic tetraplegia) [1]. These symptoms often become more apparent in the first two years of life [7].
  3. Intellectual Disability: Children with SLS typically face some degree of developmental delay or learning challenge [8].

Additionally, a significant number of children with SLS (approximately 59% to 73%) are born prematurely [9]. This is believed to be related to how the body processes fats during pregnancy [9].

The Science: Why SLS Happens

SLS is caused by mutations in the ALDH3A2 gene [8]. This gene is responsible for creating an enzyme called FALDH (fatty aldehyde dehydrogenase) [10].

Think of the FALDH enzyme as a specialized “cleanup crew” for the body [11]. Its job is to break down specific fatty substances called fatty aldehydes [12]. In children with SLS, this cleanup crew is either missing or doesn’t work correctly, leading to a toxic buildup of these fatty aldehydes [12][13].

  • In the skin: This buildup disrupts the protective barrier, causing the dryness and scaling of ichthyosis [12].
  • In the nervous system: The buildup interferes with myelin—the protective coating around nerve fibers—leading to muscle stiffness and developmental challenges [12].

What Research Tells Us

Researchers agree on the genetic cause and the biological “cleanup” failure described above [10]. However, one area that remains uncertain is the variability of the condition. Even within the same family, one child may have very mild symptoms while another is more severely affected [14][2]. Scientists are still working to understand why the same genetic mutation can lead to such different experiences [15].

Navigating the Road Ahead

Your child’s care will require a deeply coordinated, multidisciplinary effort. This guide is broken down into specific sections to help you navigate every stage of your child’s journey:

Focusing on these manageable aspects step-by-step can help provide stability as you navigate this new diagnosis.

Common questions in this guide

What is the classic triad of Sjögren-Larsson Syndrome?
The classic triad refers to the three primary features of the condition: congenital ichthyosis (dry, scaly skin present from birth), spasticity (stiff or tight muscles, especially in the limbs), and intellectual disability or developmental delays.
What causes Sjögren-Larsson Syndrome?
SLS is caused by mutations in the ALDH3A2 gene. This mutation prevents the body from producing a functional FALDH enzyme, leading to a toxic buildup of fatty substances that damage the skin barrier and the nervous system.
Is there a cure for Sjögren-Larsson Syndrome?
While there is currently no cure for this lifelong genetic condition, the symptoms are manageable. A coordinated medical team can provide treatments and therapies to improve skin comfort, enhance mobility, and support developmental progress.
Why does Sjögren-Larsson Syndrome cause muscle stiffness?
The genetic mutation causes a buildup of fatty aldehydes that interferes with myelin, which is the protective coating around nerve fibers. This disruption in the nervous system causes the muscle stiffness and tightness known as spasticity.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the current status of my child’s ALDH3A2 gene activity, and how does this affect their prognosis?
  2. 2.How frequent should our follow-ups be with neurology, dermatology, and ophthalmology to monitor the 'classic triad'?
  3. 3.What specific moisturizing or exfoliating agents do you recommend for managing my child's ichthyosis on a daily basis?
  4. 4.Can you explain the results of my child’s MRI or MRS in relation to their muscle stiffness (spasticity)?
  5. 5.Are there any local specialists or support networks you work with who have experience managing SLS?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Phenotypic and mutational spectrum of thirty-five patients with Sjögren-Larsson syndrome: identification of eleven novel ALDH3A2 mutations and founder effects.

    Abdel-Hamid MS, Issa MY, Elbendary HM, et al.

    Journal of human genetics 2019; (64(9)):859-865 doi:10.1038/s10038-019-0637-x.

    PMID: 31273323
  2. 2

    Genetic assessment of ten Egyptian patients with Sjögren-Larsson syndrome: expanding the clinical spectrum and reporting a novel ALDH3A2 mutation.

    Amr K, El-Bassyouni HT, Ismail S, et al.

    Archives of dermatological research 2019; (311(9)):721-730 doi:10.1007/s00403-019-01953-6.

    PMID: 31388754
  3. 3

    Sjögren-Larsson syndrome: a rare disease of the skin and central nervous system.

    Roy U, Das U, Pandit A, Debnath A

    BMJ case reports 2016; (2016()):10.1136/bcr-2016-215110.

    PMID: 27095813
  4. 4

    Small touches to big walks -the impact of rehabilitation on Sjögren-Larsson syndrome: A case report.

    Yolcu G, Huseynli L, Kenis-Coskun O, Karadag-Saygi E

    Journal of pediatric rehabilitation medicine 2022; (15(3)):533-537 doi:10.3233/PRM-201521.

    PMID: 35871376
  5. 5

    Clinical and molecular characterization and response to acitretin in three families with Sjögren-Larsson syndrome.

    Vural S, Vural A, Akçimen F, et al.

    International journal of dermatology 2018; (57(7)):843-848 doi:10.1111/ijd.14013.

    PMID: 29704247
  6. 6

    Novel mutations and a severe neurological phenotype in Sjögren-Larsson syndrome patients from Iran.

    Kariminejad A, Barzgar M, Bozorgmehr B, et al.

    European journal of medical genetics 2018; (61(3)):139-144 doi:10.1016/j.ejmg.2017.11.006.

    PMID: 29183715
  7. 7

    A Neurodegenerative Phenotype Associated With Sjögren-Larsson Syndrome.

    Warrack S, Love T, Rizzo WB

    Journal of child neurology 2021; (36(11)):1011-1016 doi:10.1177/08830738211029390.

    PMID: 34315315
  8. 8

    Sjögren-Larsson syndrome: a complex metabolic disease with a distinctive ocular phenotype.

    Fouzdar-Jain S, Suh DW, Rizzo WB

    Ophthalmic genetics 2019; (40(4)):298-308 doi:10.1080/13816810.2019.1660379.

    PMID: 31512987
  9. 9

    Understanding fetal factors that contribute to preterm birth: Sjögren-Larsson syndrome as a model.

    Staps P, Hogeveen M, Fuijkschot J, et al.

    Journal of perinatal medicine 2018; (46(5)):523-529 doi:10.1515/jpm-2017-0187.

    PMID: 28915122
  10. 10

    Genotype and phenotype variability in Sjögren-Larsson syndrome.

    Weustenfeld M, Eidelpes R, Schmuth M, et al.

    Human mutation 2019; (40(2)):177-186 doi:10.1002/humu.23679.

    PMID: 30372562
  11. 11

    Ciliopathy: Sjögren-Larsson Syndrome.

    Tsang SH, Aycinena ARP, Sharma T

    Advances in experimental medicine and biology 2025; (1467()):195-196 doi:10.1007/978-3-031-72230-1_36.

    PMID: 40736838
  12. 12

    Compound heterozygous mutations in the ALDH3A2 gene cause Sjögren-Larsson syndrome: a case report.

    Liu YD, Lin HJ, Li CY, et al.

    The International journal of neuroscience 2020; (130(11)):1156-1160 doi:10.1080/00207454.2020.1716750.

    PMID: 31944864
  13. 13

    Disturbed brain ether lipid metabolism and histology in Sjögren-Larsson syndrome.

    Staps P, Rizzo WB, Vaz FM, et al.

    Journal of inherited metabolic disease 2020; (43(6)):1265-1278 doi:10.1002/jimd.12275.

    PMID: 32557630
  14. 14

    Sjögren-Larsson syndrome: The mild end of the phenotypic spectrum.

    Staps P, van Gaalen J, van Domburg P, et al.

    JIMD reports 2020; (53(1)):61-70 doi:10.1002/jmd2.12099.

    PMID: 32395410
  15. 15

    Clinical, biochemical, and genetic aspects of Sjögren-Larsson syndrome.

    Cho KH, Shim SH, Kim M

    Clinical genetics 2018; (93(4)):721-730 doi:10.1111/cge.13058.

    PMID: 28543186

This guide provides educational information for families facing a new Sjögren-Larsson Syndrome diagnosis. It does not replace professional medical advice from your child's neurology, dermatology, and genetics care team.

Get notified when new evidence is published on Sjögren-Larsson syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.